Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)

A Randomized, Open-Label, Comparative Trial to Evaluate the Effects on Ovarian Function of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 ug Ethinyl Estradiol (EE)

The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.

Inclusion Criteria:

• Willing to use COC for at least 6 cycles.
• 18 - 35 years of age at screening.
• Body Mass Index (BMI) of >/= 17 and </= 35.
• Good physical and mental health.
• Willing to use condoms as the sole contraceptive method during screening cycle and 1 post-treatment cycle.
• Willing to give informed consent.

Exclusion Criteria:

• Contraindications for contraceptive steroids (general).
• Additional contraindications (renal, hepatic or adrenal insufficiency).
• Breastfeeding.
• Present use (or use within 2 months prior to start of the trial medication) of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex

steroids (other than pre- and post treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St. John's Wort).

• Administration of any other investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.
• Abnormal cervical smear at screening, or documentation of an abnormal smear performed within 6 months before screening.
• Clinically relevant abnormal laboratory result at screening as judged by the investigator.